We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 9 of 85 for:    Recruiting, Not yet recruiting, Available Studies | "Muscular Dystrophies"

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Participants With Duchenne Muscular Dystrophy (DMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03375255
Recruitment Status : Recruiting
First Posted : December 18, 2017
Last Update Posted : January 26, 2018
Sponsor:
Information provided by (Responsible Party):
Sarepta Therapeutics

December 12, 2017
December 18, 2017
January 26, 2018
December 11, 2017
January 2019   (Final data collection date for primary outcome measure)
Number of Participants with Adverse Events (AEs) [ Time Frame: Up to 14 Weeks ]
An AE is any untoward medical occurrence in a clinical trial patient, which does not necessarily have a causal relationship with the investigational drug. An AE can, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurs during or after administration of the study drug whether or not considered related to the study drug.
Same as current
Complete list of historical versions of study NCT03375255 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Participants With Duchenne Muscular Dystrophy (DMD)
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of 5 escalating doses of SRP-5051 administered as a single dose to participants with DMD amenable to exon 51 skipping treatment.
Not Provided
Interventional
Phase 1
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Muscular Dystrophy, Duchenne
Drug: SRP-5051
Single dose of SRP-5051 administered as an intravenous (IV) infusion.
Experimental: SRP-5051
Participants will be sequentially assigned to receive one of the 5 escalating dose levels of SRP-5051 on Day 1.
Intervention: Drug: SRP-5051
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
January 2019
January 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Has a genetic diagnosis of DMD and an out-of-frame deletion mutation of the DMD gene amenable to exon 51 skipping treatment
  • Has been on a stable dose of oral corticosteroids for at least 12 weeks prior to study drug administration, or has not received corticosteroids for at least 12 weeks prior to study drug administration

Exclusion Criteria:

  • Has a left ventricular ejection fraction (LVEF) less than (<) 40 percent (%) based on an echocardiogram (ECHO) performed within 3 months prior to Screening or at the Screening visit
  • Has a QTcF >= 450 milliseccond (msec) on the Screening electrocardiogram (ECG)
  • Initiation or change of dosing (except for modifications to accommodate changes in weight) within 12 weeks prior to Screening for any of the following: angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blocking agents (ARBs), beta-blockers, potassium
  • Must not require antiarrhythmic and/or antidiuretic therapy for heart failure
  • Forced vital capacity (FVC) <50% of predicted value and/or requirement for nocturnal ventilation
  • Known kidney disease or had an acute kidney injury within 6 months
Sexes Eligible for Study: Male
Gender Based Eligibility: Yes
12 Years and older   (Child, Adult, Senior)
No
Contact: Medical Information +1-888-727-3782 medinfo@sarepta.com
United States
 
 
NCT03375255
5051-101
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Sarepta Therapeutics
Sarepta Therapeutics
Not Provided
Study Director: Jon Lu, MD,PHD Sarepta Therapeutics
Study Director: Catherine Stehman-Breen, MD,MS Sarepta Therapeutics
Sarepta Therapeutics
January 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP